Cadila Healthcare

Cadila Healthcare, Zydus Wellness to buy Heinz India for Rs 4,595 cr; Complan, Glucon D, Nycil brands part of deal

The transaction is proposed to be financed by a mix of equity and debt

Zydus Group clinches in-licensing deal with Swiss co Neovii to market Grafalon drug

Grafalon offers a specific advantage of efficacy and better safety profile through targeted immunosuppression

Cadila Healthcare gets EIR for Ahmedabad plant from USFDA

The EIR report is given to an establishment after the completion of an inspection by the USFDA

Cadila Healthcare Q1 net dips 23% to Rs 356 crore

Consolidated total income from operations of the company stood at Rs 2,287.1 crore for the quarter

Warning letters for pharma cos galore: Now Cadila Healthcare faces USFDA heat, stock tanks 16%

The Ahmedabad-headquartered company received a warning letter for its Moraiya formulation facility and Ahmedabad API facility

Cadila Healthcare Q3 profit rises 52% to Rs 282 cr

Drug firm Cadila Healthcare reported a 52 percent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended 31 December 2014 on back of robust sales.

Cadila gets approval to market new diabetes drug Lipaglyn in India

Cadila gains 4% as US FDA revokes warning on unit

The warning was issued in June 2011, saying the facilities in the plant were not conforming to the US FDA guidelines and that there were fears the company's drugs from the unit may get adulterated.

Broker Alert: Dump Voltas, Exide has the right mix

Voltas' cooling division is facing increased pressure on the margin front as other players are offering freebies and discounts to liquidate existing inventories.

Zydus gets FDA tentative nod to market anti-diabetic tablets in US

According to IMS health the estimated sales in 2014 for Glipizide ER tablets is $90.1 million